Biotherapeutics News and Research

RSS
Experimental antiviral drug for COVID-19 shows effectiveness in hamster models

Experimental antiviral drug for COVID-19 shows effectiveness in hamster models

Gyros Protein Technologies introduces Gyrolab Bioaffy 4000 CD to extend sensitivity of immunoassay CD range

Gyros Protein Technologies introduces Gyrolab Bioaffy 4000 CD to extend sensitivity of immunoassay CD range

Horizon Discovery licenses CHOSOURCE to Sanyou Biopharmaceuticals Co.

Horizon Discovery licenses CHOSOURCE to Sanyou Biopharmaceuticals Co.

Researchers successfully edit SIV virus from genomes of non-human primates

Researchers successfully edit SIV virus from genomes of non-human primates

Unique training program is bolstering Canada’s capacity to manufacture novel biotherapeutics

Unique training program is bolstering Canada’s capacity to manufacture novel biotherapeutics

Stewart Kay joins Adaptate Biotherapeutics as Chief Business Officer

Stewart Kay joins Adaptate Biotherapeutics as Chief Business Officer

New DNA-cutting tool could advance gene editing for novel treatments

New DNA-cutting tool could advance gene editing for novel treatments

Novel microfluidic approach to fight cancer could greatly benefit patients

Novel microfluidic approach to fight cancer could greatly benefit patients

Immunotherapy benefits patients with gastric and esophageal cancers, new data shows

Immunotherapy benefits patients with gastric and esophageal cancers, new data shows

Avacta to launch Affimer-based ELISA test for SARS-CoV-2 virus detection

Avacta to launch Affimer-based ELISA test for SARS-CoV-2 virus detection

New Gyrolab AAVX Titer Kit launched to support the development cell and gene therapies

New Gyrolab AAVX Titer Kit launched to support the development cell and gene therapies

Avacta enters into manufacturing agreement with Abingdon Health for rapid SARS-CoV-2 antigen test

Avacta enters into manufacturing agreement with Abingdon Health for rapid SARS-CoV-2 antigen test

New diagnostic tool can predict cancer patients' response to immunotherapy

New diagnostic tool can predict cancer patients' response to immunotherapy

Avacta expands multi-target collaboration with LG Chem Life Sciences

Avacta expands multi-target collaboration with LG Chem Life Sciences

Neil Bell appointed as Chief Development Officer of Avacta Life Sciences

Neil Bell appointed as Chief Development Officer of Avacta Life Sciences

Avacta appoints COVID-19 rapid antigen test manufacturing partner

Avacta appoints COVID-19 rapid antigen test manufacturing partner

Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy

Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy

Avacta provides update on clinical validation of Adeptrix COVID-19 diagnostic test

Avacta provides update on clinical validation of Adeptrix COVID-19 diagnostic test

Avacta provides update on clinical validation of Adeptrix COVID-19 diagnostic test

Avacta provides update on clinical validation of Adeptrix COVID-19 diagnostic test

Avacta and Integumen team up for detection of novel coronavirus in waste water

Avacta and Integumen team up for detection of novel coronavirus in waste water